Previous close | 13.36 |
Open | 13.27 |
Bid | 13.10 x 3200 |
Ask | 13.40 x 800 |
Day's range | 13.22 - 13.29 |
52-week range | 13.01 - 17.03 |
Volume | |
Avg. volume | 1,641,250 |
Market cap | 41.882B |
Beta (5Y monthly) | 0.54 |
PE ratio (TTM) | 35.89 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.64 (4.78%) |
Ex-dividend date | 28 Sept 2023 |
1y target est | N/A |
Comprehensive Analysis of Q1 2024 Earnings and Strategic Developments
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.